Examples of using Azopt in English and their translations into Italian
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
-
Official/political
The most common side effects with Azopt(seen in between 1
What AZOPT looks like and contents of the pack.
A clinical trial was conducted with AZOPT in 32 paediatric patients less than 6 years of age,
If you stop using AZOPT without speaking to your doctor,
AZOPT is not to be used by infants,
After using AZOPT, press a finger to the corner of your eye,
Use in children The efficacy and safety of AZOPT in patients below the age of 18 have not been established
Use in hepatic and renal impairment AZOPT has not been studied in patients with hepatic impairment
AZOPT has not been studied in patients with severe renal impairment(creatinine clearance<
Potential rebound effects following cessation of treatment with AZOPT have not been studied;
see section 1 WHAT AZOPT IS AND WHAT IT IS USED FOR), talk to your doctor.
the dose is one drop of AZOPT in the conjunctival sac of the affected eye(s) twice daily.
Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZOPT is therefore contra-indicated in such patients see also 4.3.
The IOP-reducing effect of AZOPT as adjunctive therapy to the prostaglandin analogue travoprost was studied.
the efficacy of AZOPT was similar to that seen previously in adults, with mean IOP
This helps to stop AZOPT getting into the rest of the body.• If you take drops in both eyes, repeat the steps
If you wear contact lenses you should remove them prior to the application of AZOPT and wait at least 15 minutes after instillation of the dose before putting your lenses back in.
The safety and efficacy of AZOPT have been studied in a small number of paediatric patients less than 6 years of age see also 4.4,
The safety and efficacy of AZOPT in infants, children
AZOPT is indicated to decrease elevated intraocular pressure in:• ocular hypertension• open-angle glaucoma as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contraindicated,
